{"id":49035,"date":"2025-11-26T15:39:52","date_gmt":"2025-11-26T07:39:52","guid":{"rendered":"https:\/\/flcube.com\/?p=49035"},"modified":"2025-11-26T15:39:53","modified_gmt":"2025-11-26T07:39:53","slug":"kelonia-jnj-partnership-targets-in-vivo-car-t-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49035","title":{"rendered":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Kelonia Therapeutics<\/strong> announced a strategic collaboration with <strong>Johnson &amp; Johnson<\/strong> (J&amp;J, <a href=\"https:\/\/www.google.com\/finance\/quote\/JNJ:NYSE\">NYSE: JNJ<\/a>) to develop <strong>in vivo CAR-T cell therapies<\/strong> using Kelonia\u2019s proprietary <strong>iGPS platform<\/strong>, with J&amp;J gaining access to the lead candidate KLN-1010 for multiple myeloma.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Kelonia Therapeutics &amp; Johnson &amp; Johnson<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>iGPS (in vivo Gene Positioning System) platform<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>In vivo CAR-T therapies for J&amp;J priority targets<\/td><\/tr><tr><td><strong>Lead Candidate<\/strong><\/td><td>KLN-1010 (in vivo BCMA CAR-T)<\/td><\/tr><tr><td><strong>J&amp;J\u2019s Role<\/strong><\/td><td>Advance molecules through development and commercialization<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Not disclosed; includes upfront, milestones, and royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-update-kln-1010\">Pipeline Update \u2013 KLN-1010<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Multiple myeloma (\u22653 prior lines: PI, IMiD, CD38 antibody)<\/td><\/tr><tr><td><strong>Patients Treated<\/strong><\/td><td>First 3 patients<\/td><\/tr><tr><td><strong>MRD Negativity<\/strong><\/td><td>100% at Month 1<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>Sustained for 3 months; longest patient remains MRD negative<\/td><\/tr><tr><td><strong>Lymphodepletion<\/strong><\/td><td>Not required<\/td><\/tr><tr><td><strong>Leukapheresis<\/strong><\/td><td>Not required<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>No DLTs; No Grade \u22653 CRS or ICANS<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> In vivo CAR-T delivery via viral vector directly into patient, eliminating ex vivo cell manufacturing<\/li>\n\n\n\n<li><strong>Advantages:<\/strong> <strong>Improved accessibility<\/strong>, <strong>reduced treatment burden<\/strong>, <strong>no hospitalization<\/strong> for cell processing<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Potential to revolutionize traditional CAR-T paradigm (which requires 2\u20114 week manufacturing)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Multiple Myeloma Market<\/strong><\/td><td>$28\u202fbillion globally (2024)<\/td><\/tr><tr><td><strong>Relapsed\/Refractory Patients<\/strong><\/td><td>~50,000 annually in US\/EU<\/td><\/tr><tr><td><strong>Traditional CAR-T Sales<\/strong><\/td><td>$2.5\u202fbillion (2024)<\/td><\/tr><tr><td><strong>In Vivo CAR-T Potential<\/strong><\/td><td><strong>$5\u20118\u202fbillion<\/strong> peak if approved (addressing 3\u20114\u00d7 more patients due to accessibility)<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong> First in vivo BCMA CAR-T with clinical data; J&amp;J partnership provides scale<\/td><td><\/td><\/tr><tr><td><strong>Next Catalyst:<\/strong> Phase\u202f1 expansion data expected <strong>Q2\u202f2026<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Kelonia\u2011J&amp;J collaboration, KLN-1010 development, and market potential. Actual results may differ materially due to risks including clinical trial outcomes, manufacturing scale\u2011up, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kelonia Therapeutics announced a strategic collaboration with Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) to develop&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49037,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[21,150,149,4475,858],"class_list":["post-49035","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-car-t","tag-jj","tag-johnson-johnson","tag-kelonia-therapeutics","tag-nyse-jnj"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kelonia Therapeutics announced a strategic collaboration with Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&amp;J gaining access to the lead candidate KLN-1010 for multiple myeloma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49035\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Kelonia Therapeutics announced a strategic collaboration with Johnson &amp; Johnson (J&amp;J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&amp;J gaining access to the lead candidate KLN-1010 for multiple myeloma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49035\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T07:39:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T07:39:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma\",\"datePublished\":\"2025-11-26T07:39:52+00:00\",\"dateModified\":\"2025-11-26T07:39:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2606.webp\",\"keywords\":[\"CAR-T\",\"J&amp;J\",\"Johnson &amp; Johnson\",\"Kelonia Therapeutics\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49035#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49035\",\"name\":\"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2606.webp\",\"datePublished\":\"2025-11-26T07:39:52+00:00\",\"dateModified\":\"2025-11-26T07:39:53+00:00\",\"description\":\"Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&J gaining access to the lead candidate KLN-1010 for multiple myeloma.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49035\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2606.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2606.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49035#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&J gaining access to the lead candidate KLN-1010 for multiple myeloma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49035","og_locale":"en_US","og_type":"article","og_title":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma","og_description":"Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&J gaining access to the lead candidate KLN-1010 for multiple myeloma.","og_url":"https:\/\/flcube.com\/?p=49035","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T07:39:52+00:00","article_modified_time":"2025-11-26T07:39:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49035#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49035"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma","datePublished":"2025-11-26T07:39:52+00:00","dateModified":"2025-11-26T07:39:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49035"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49035#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","keywords":["CAR-T","J&amp;J","Johnson &amp; Johnson","Kelonia Therapeutics","NYSE: JNJ"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49035#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49035","url":"https:\/\/flcube.com\/?p=49035","name":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49035#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49035#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","datePublished":"2025-11-26T07:39:52+00:00","dateModified":"2025-11-26T07:39:53+00:00","description":"Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop in vivo CAR-T cell therapies using Kelonia\u2019s proprietary iGPS platform, with J&J gaining access to the lead candidate KLN-1010 for multiple myeloma.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49035#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49035"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49035#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","width":1080,"height":608,"caption":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49035#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2606.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49035"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49035\/revisions"}],"predecessor-version":[{"id":49038,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49035\/revisions\/49038"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49037"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}